Resources

At the end of the day, humans are mammals. What Fauna is really doing is looking at ‘human’ genes that are helping these other species resist and reverse disease. We’re using extreme biology to look back at our own evolutionary history and find ‘the answer inside us’. We’re NOT putting squirrel genes into people!

Hibernators are particularly well suited for this approach because almost every major group of mammals has hibernators (including primates!). The gray mouse lemur in Madagascar hibernates pretty similarly to ground squirrels. This means they are tapping into core mammalian genetic pathways that are very similar across very different species. This is the reason that at Fauna Bio we even have T-shirts at Fauna that say “I’m 89% squirrel”!

To help us translate these insights into therapies for humans, we layer on many hundreds of different datasets from humans and then test our therapies in human disease models, to give us confidence that the same genes protecting ground squirrels from heart damage can protect humans in heart failure (as one example).

What new treatments are you developing from this approach?

We are creating safer, more effective therapeutics for human diseases based on evolutionary adaptations to similar problems.

Our lead program, Faun1083, is a truly novel approach to a type of heart failure known as Heart Failure with preserved Ejection Fraction (HFpEF), which is about half (50%) of all heart failure cases around the world and is increasing as people get older and with obesity and metabolic disease. This is a drug that is entering the final set of safety studies (IND-enabling studies) that we need to be able to start clinical studies in humans.

This therapy came directly from learning how species like the 13-lined ground squirrel protect their hearts from damage that occurs during hibernation.

Are you using AI in your discovery approach? How does the platform work?

Yes! In two main ways:

Because our custom knowledge graph, Centaur, now contains not only Fauna Bio data, but data from more than 35 large biomedical datasets with 1 million nodes, 38 million edges it is too large for any human to glean insights from it without the use of AI. Our graph neural network to analyze this knowledge graph has a billion model parameters!
In order to enhance speed and scalability of drug discovery, we have specially trained AI agents (collectively called Fauna Brain) that can replicate the output of several days of effort by our team of highly trained drug hunters in a matter of minutes. This system is an excellent example of ‘human in the loop’ as our AI engineer worked directly with team members doing drug discovery with the ConvergenceAI platform to have Fauna Brain learn how to use the platform and improve its predictions. This is a living system that continues to learn and improve every time we use it for discovery.

Why is using ‘extreme’ animal data an advantage when it comes to drug discovery?

Using extreme animal physiology enables Fauna Bio to do discovery from <100 samples vs. the more than >30,000 samples we’d need to try and get similar insights from human genomics (if we could even find signal at all…).

Our lead program, Faun1083, came from a study with just 60 samples from ground squirrels, almost 3 orders of magnitude less data than you’d need from human studies. This is because we are sampling tissues at the precise times when they are repairing themselves and it makes it much more obvious what genes are involved in that protection.

We still use all that human data, but to confirm findings from the ground squirrels as we can then look at humans that have natural mutations in genes we find with our approach and ask if we see correlations to diseases like heart failure. For our lead program, Faun1083, humans with mutations in the target of that program have links to changes in heart damage markers, changes in fuel utilized by the heart and changes relating to pulmonary hypertension, a common occurrence in patients with HFpEF.

Ok, so I get hibernators are ‘cool’ - what about other species? How many species have this type of unique resistance to disease?

Our internal innovations team has identified > 35 other species with disease resistance traits, in diseases like neurodegeneration, metabolic disease, chronic kidney disease and even aging. The amazing pipeline and partnerships we’ve been able to build have all been from 1 species, the remarkable 13-lined ground squirrel, but its just the tip of the iceberg!

Company

About Us Our Approach Resources

Contact

hello@faunabio.com

6460 Hollis St., Suite A Emeryville, CA 94608

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.

Featured content

AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets

AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets

Fauna Bio Featured in WSJ: Studies Animal Genomes for Clues to Human Diseases

Fauna Bio Featured in WSJ: Studies Animal Genomes for Clues to Human Diseases

Fauna Bio CEO interviewed by Drug Discovery and Development on the advantages of tapping extreme mammals for human disease breakthroughs

Fauna Bio CEO interviewed by Drug Discovery and Development on the advantages of tapping extreme mammals for human disease breakthroughs

Latest from Fauna Bio

Think marathon runners have amazing metabolism? Try being an elephant seal!

Think marathon runners have amazing metabolism? Try being an elephant seal!

Think marathon runners have amazing metabolism? Try being an elephant seal!

Think marathon runners have amazing metabolism? Try being an elephant seal!

Fauna Bio CEO, Ashley Zehnder, invited as an emerging life science founder for the SF Business Time Biotech Summit

Fauna Bio CEO, Ashley Zehnder, invited as an emerging life science founder for the SF Business Time Biotech Summit

Fauna Bio CEO, Ashley Zehnder, invited as an emerging life science founder for the SF Business Time Biotech Summit

Fauna Bio CEO, Ashley Zehnder, invited as an emerging life science founder for the SF Business Time Biotech Summit

Can hibernating animals offer clues to Alzheimer's? Three women from Stanford think so

Can hibernating animals offer clues to Alzheimer's? Three women from Stanford think so

Can hibernating animals offer clues to Alzheimer's? Three women from Stanford think so

Can hibernating animals offer clues to Alzheimer's? Three women from Stanford think so

In order to cure disease, we need to remember we are also animals

In order to cure disease, we need to remember we are also animals

In order to cure disease, we need to remember we are also animals

In order to cure disease, we need to remember we are also animals

Fauna Bio is interviewed on the Anatomy of Next podcast

Fauna Bio is interviewed on the Anatomy of Next podcast

Fauna Bio is interviewed on the Anatomy of Next podcast

Fauna Bio is interviewed on the Anatomy of Next podcast

Fauna Bio and collaborators discuss the potential for human hibernation in NBC News interview

Fauna Bio and collaborators discuss the potential for human hibernation in NBC News interview

Fauna Bio and collaborators discuss the potential for human hibernation in NBC News interview

Fauna Bio and collaborators discuss the potential for human hibernation in NBC News interview

Fauna Bio is featured in Business Insider

Fauna Bio is featured in Business Insider

Fauna Bio is featured in Business Insider

Fauna Bio is featured in Business Insider

Science of rhythm nightlife at the California Academy of Sciences

Science of rhythm nightlife at the California Academy of Sciences

Science of rhythm nightlife at the California Academy of Sciences

Science of rhythm nightlife at the California Academy of Sciences

Fauna bio receives investment from the longevity fund and is accepted into the age1 accelerator program

Fauna bio receives investment from the longevity fund and is accepted into the age1 accelerator program

Fauna bio receives investment from the longevity fund and is accepted into the age1 accelerator program

Fauna bio receives investment from the longevity fund and is accepted into the age1 accelerator program

FB-1083 demonstrates potent efficacy in preclinical models of Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension

FB-1083 demonstrates potent efficacy in preclinical models of Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension

FB-1083 demonstrates potent efficacy in preclinical models of Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension

FB-1083 demonstrates potent efficacy in preclinical models of Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension

Foreign body response from implanted cortical-neuro probes in the spiny mouse (Acomys)

Foreign body response from implanted cortical-neuro probes in the spiny mouse (Acomys)

Foreign body response from implanted cortical-neuro probes in the spiny mouse (Acomys)

Foreign body response from implanted cortical-neuro probes in the spiny mouse (Acomys)

No results found.

Frequently Asked Questions